RLMD
Relmada Therapeutics, Inc. · Healthcare
Director Paul Edward Kelly sold $126K of Relmada Therapeutics, Inc.
Sold$125,565
$35.18Price
3,569Shares
−2%Stake
What RLMD did after the filing
- The stock from Wed, Feb 10 close, $34.95
- −4.9%
- S&P 500, same days
- +0.2%
Measured over 30 trading days, to the Mar 25 close.
Traded Mon, Feb 8. Filed Wed, Feb 10, 2:25 PM ET, during the session. Returns use the Feb 10 close and the Mar 25 close. Not investment advice.